What is Dynavax Technolo's earnings per share (EPS)?

Dynavax Technolo (DVAX) reported diluted earnings per share of $0.20 for fiscal year 2024. This represents a 500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dynavax Technolo Financials

DVAX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Dynavax Technolo (DVAX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DVAX FY2024 2026-04-22

Dynavax's economics are driven by high gross margins that only become durable profit when sales absorb a heavy operating-cost base.

FY2024's gross margin reached 82.2%, up from 78.4% in FY2023, showing the product itself remained highly profitable. Yet SG&A plus R&D were about $231.9M against gross profit of $227.8M, which explains why operating profitability still lagged despite better unit economics.

The liquidity cushion remains unusually large: current assets of $849M versus current liabilities of $78.6M mean near-term obligations are not what defines the capital structure. Cash fell, but free cash flow stayed positive at $60.2M, and the larger drain was a $100M share buyback.

Across recent years, operating cash flow remained positive even though net income swung from $293.2M to a loss and then back to profit. That makes earnings quality a year-specific story here: accounting profit can move sharply, while cash generation has been steadier than the income statement suggests.

Financial Health Signals

Financial Profile 57/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Dynavax Technolo's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Dynavax Technolo has an operating margin of -1.5%, meaning the company retains $-1 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is up from -15.9% the prior year.

Growth

Dynavax Technolo's revenue surged 19.4% year-over-year to $277.2M, reflecting rapid business expansion. This strong growth earns a score of 0/100.

Leverage

Dynavax Technolo carries a low D/E ratio of 0.65, meaning only $0.65 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.80, Dynavax Technolo holds $10.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Dynavax Technolo converts 21.7% of revenue into free cash flow ($60.2M). This strong cash generation earns a score of 87/100.

Returns

Dynavax Technolo's ROE of 4.6% shows moderate profitability relative to equity, earning a score of 38/100. This is up from -1.0% the prior year.

Piotroski F-Score Strong

7/9

Dynavax Technolo passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.44x

For every $1 of reported earnings, Dynavax Technolo generates $2.44 in operating cash flow ($66.5M OCF vs $27.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

-0.6x

Dynavax Technolo earns $-0.6 in operating income for every $1 of interest expense (-$4.1M vs $6.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$277.2M

YoY+19.4%

5Y CAGR+51.1%

10Y CAGR+38.0%

Dynavax Technolo generated $277.2M in revenue in fiscal year 2024. This represents an increase of 19.4% from the prior year.

EBITDA

$505K

YoY+101.5%

Dynavax Technolo's EBITDA was $505K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 101.5% from the prior year.

Net Income

$27.3M

YoY+527.4%

Dynavax Technolo reported $27.3M in net income in fiscal year 2024. This represents an increase of 527.4% from the prior year.

EPS (Diluted)

$0.20

YoY+500.0%

Dynavax Technolo earned $0.20 per diluted share (EPS) in fiscal year 2024. This represents an increase of 500.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$60.2M

YoY-37.6%

Dynavax Technolo generated $60.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 37.6% from the prior year.

Cash & Debt

$95.9M

YoY-36.2%

5Y CAGR+19.2%

10Y CAGR+6.8%

Dynavax Technolo held $95.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

125M

YoY-3.1%

5Y CAGR+8.4%

10Y CAGR+16.9%

Dynavax Technolo had 125M shares outstanding in fiscal year 2024. This represents a decrease of 3.1% from the prior year.

Margins & Returns

Gross Margin

82.2%

YoY+3.8pp

5Y CAGR+11.0pp

Dynavax Technolo's gross margin was 82.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.8 percentage points from the prior year.

Operating Margin

-1.5%

YoY+14.4pp

5Y CAGR+381.4pp

10Y CAGR+826.2pp

Dynavax Technolo's operating margin was -1.5% in fiscal year 2024, reflecting core business profitability. This is up 14.4 percentage points from the prior year.

Net Margin

9.8%

YoY+12.6pp

5Y CAGR+443.1pp

10Y CAGR+832.2pp

Dynavax Technolo's net profit margin was 9.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 12.6 percentage points from the prior year.

Return on Equity

4.6%

YoY+5.6pp

5Y CAGR+1845.3pp

10Y CAGR+94.9pp

Dynavax Technolo's ROE was 4.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 5.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$61.5M

YoY+12.1%

5Y CAGR-0.3%

10Y CAGR-3.1%

Dynavax Technolo invested $61.5M in research and development in fiscal year 2024. This represents an increase of 12.1% from the prior year.

Share Buybacks

$100.0M

Dynavax Technolo spent $100.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$6.4M

YoY+54.8%

5Y CAGR-22.3%

10Y CAGR+14.3%

Dynavax Technolo invested $6.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 54.8% from the prior year.

DVAX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$277.2M+19.4%	$232.3M-67.9%	$722.7M+64.5%	$439.4M+844.0%	$46.6M+32.2%	$35.2M
Cost of Revenue	$49.4M-1.4%	$50.2M-80.9%	$262.2M+51.0%	$173.6M+1421.2%	$11.4M+12.2%	$10.2M
Gross Profit	$227.8M+25.1%	$182.1M-60.5%	$460.5M+73.2%	$265.9M+656.6%	$35.1M+40.3%	$25.0M
R&D Expenses	$61.5M+12.1%	$54.9M+17.8%	$46.6M+44.6%	$32.2M+12.7%	$28.6M-54.1%	$62.3M
SG&A Expenses	$170.4M+11.4%	$152.9M+16.4%	$131.4M+31.2%	$100.2M+26.4%	$79.3M+5.7%	$75.0M
Operating Income	-$4.1M+88.9%	-$37.0M-113.1%	$283.5M+110.8%	$134.5M+296.7%	-$68.4M+49.3%	-$134.8M
Interest Expense	$6.8M+0.5%	$6.8M+0.4%	$6.7M-39.8%	$11.2M-41.4%	$19.1M+12.3%	$17.0M
Income Tax	$3.5M+75.4%	$2.0M+76.9%	$1.1M+41.5%	$808K	$0	$0
Net Income	$27.3M+527.4%	-$6.4M-102.2%	$293.2M+282.1%	$76.7M+202.0%	-$75.2M+50.7%	-$152.6M
EPS (Diluted)	$0.20+500.0%	$-0.05-102.5%	$1.97+245.6%	$0.57+173.1%	$-0.78+63.9%	$-2.16

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$94.9M-0.6%	$95.4M+40.0%	$68.2M-5.4%	$72.0M-10.7%	$80.6M+9.3%	$73.8M+45.3%	$50.8M-8.6%	$55.6M
Cost of Revenue	$14.4M+2.6%	$14.0M+1.9%	$13.8M+2.7%	$13.4M+2.5%	$13.1M+9.2%	$12.0M+9.3%	$11.0M+26.2%	$8.7M
Gross Profit	$80.5M-1.1%	$81.4M+49.7%	$54.4M-7.2%	$58.6M-13.2%	$67.5M+9.3%	$61.8M+55.2%	$39.8M-15.1%	$46.9M
R&D Expenses	$19.1M+15.0%	$16.6M-14.2%	$19.4M+3.8%	$18.7M+29.6%	$14.4M-3.7%	$14.9M+10.5%	$13.5M-4.2%	$14.1M
SG&A Expenses	$40.1M-20.4%	$50.4M+5.6%	$47.7M+14.7%	$41.6M-3.4%	$43.1M+3.4%	$41.7M-5.5%	$44.1M+6.7%	$41.3M
Operating Income	$21.3M+47.4%	$14.4M+161.1%	-$23.6M-1347.0%	-$1.6M-116.2%	$10.1M+94.0%	$5.2M+129.3%	-$17.8M-109.3%	-$8.5M
Interest Expense	$1.6M+0.1%	$1.6M-3.0%	$1.7M-0.6%	$1.7M+0.2%	$1.7M+0.1%	$1.7M+0.2%	$1.7M+0.2%	$1.7M
Income Tax	$1.5M-40.2%	$2.5M+240.5%	-$1.8M-407.3%	$578K-74.0%	$2.2M-36.8%	$3.5M+226.8%	-$2.8M-457.3%	$777K
Net Income	$26.9M+43.8%	$18.7M+119.5%	-$96.1M-1463.1%	$7.0M-59.9%	$17.6M+54.5%	$11.4M+230.6%	-$8.7M-4082.2%	$219K
EPS (Diluted)	$0.21+50.0%	$0.14+118.2%	$-0.77	N/A	$0.12+50.0%	$0.08+214.3%	$-0.07	N/A

DVAX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$986.3M-1.1%	$997.1M+1.1%	$985.9M-5.1%	$1.0B+194.2%	$353.3M+26.6%	$279.1M
Current Assets	$848.9M-1.2%	$859.1M-6.3%	$917.0M-5.7%	$972.5M+235.3%	$290.0M+39.0%	$208.7M
Cash & Equivalents	$95.9M-36.2%	$150.3M-25.6%	$202.0M-53.7%	$436.2M+1260.0%	$32.1M-19.6%	$39.9M
Inventory	$70.1M+31.5%	$53.3M-10.4%	$59.4M-3.1%	$61.3M-3.7%	$63.7M+54.1%	$41.3M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.9M-5.9%	$2.1M+3.0%	$2.0M-5.6%	$2.1M-7.5%	$2.3M+10.4%	$2.1M
Total Liabilities	$389.5M+3.8%	$375.0M-7.4%	$404.8M-50.4%	$816.9M+177.3%	$294.6M+8.8%	$270.8M
Current Liabilities	$78.6M+26.4%	$62.2M-58.6%	$150.1M-73.0%	$556.4M+618.8%	$77.4M+45.9%	$53.0M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$179.8M+0.7%	$178.6M
Total Equity	$596.8M-4.1%	$622.1M+7.1%	$581.0M+161.3%	$222.4M+278.9%	$58.7M+608.0%	$8.3M
Retained Earnings	-$903.3M+2.9%	-$930.6M-0.7%	-$924.2M+24.1%	-$1.2B+5.9%	-$1.3B-6.2%	-$1.2B

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$946.5M+3.1%	$918.4M-2.9%	$945.9M-4.1%	$986.3M-7.1%	$1.1B+4.5%	$1.0B+3.0%	$986.6M-1.1%	$997.1M
Current Assets	$814.3M+3.6%	$785.7M-3.7%	$816.0M-3.9%	$848.9M-8.3%	$926.2M+5.0%	$882.0M+3.6%	$851.3M-0.9%	$859.1M
Cash & Equivalents	$160.2M+61.7%	$99.1M+91.6%	$51.7M-46.1%	$95.9M-19.7%	$119.3M+6.1%	$112.5M-14.8%	$132.0M-12.1%	$150.3M
Inventory	$73.3M-3.2%	$75.7M+1.7%	$74.4M+6.2%	$70.1M+12.3%	$62.4M-0.1%	$62.5M+1.1%	$61.8M+16.0%	$53.3M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$2.2M0.0%	$2.2M+8.5%	$2.0M+4.2%	$1.9M-6.9%	$2.1M+4.2%	$2.0M-0.7%	$2.0M-2.2%	$2.1M
Total Liabilities	$412.4M-2.8%	$424.3M+2.2%	$415.0M+6.6%	$389.5M+2.3%	$380.6M+1.9%	$373.5M+1.5%	$368.1M-1.9%	$375.0M
Current Liabilities	$106.8M-9.6%	$118.2M+72.9%	$68.4M-13.0%	$78.6M+12.3%	$70.0M+12.6%	$62.2M+11.1%	$56.0M-10.0%	$62.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$534.1M+8.1%	$494.2M-6.9%	$530.9M-11.0%	$596.8M-12.4%	$681.4M+6.0%	$642.8M+3.9%	$618.5M-0.6%	$622.1M
Retained Earnings	-$953.7M+2.7%	-$980.7M+1.9%	-$999.4M-10.6%	-$903.3M+0.8%	-$910.3M+1.9%	-$927.9M+1.2%	-$939.3M-0.9%	-$930.6M

DVAX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$66.5M-33.9%	$100.6M+60.3%	$62.7M-81.3%	$335.5M+463.7%	-$92.3M+23.9%	-$121.3M
Capital Expenditures	$6.4M+54.8%	$4.1M-42.5%	$7.1M-24.7%	$9.5M+132.7%	$4.1M-81.8%	$22.4M
Free Cash Flow	$60.2M-37.6%	$96.5M+73.6%	$55.6M-83.0%	$326.1M+438.5%	-$96.3M+32.9%	-$143.7M
Investing Cash Flow	-$18.0M+88.3%	-$153.9M+51.3%	-$316.0M-2321.4%	$14.2M+153.6%	-$26.5M+38.0%	-$42.8M
Financing Cash Flow	-$102.0M-7460.5%	$1.4M-92.9%	$19.5M-65.0%	$55.8M-49.1%	$109.5M-29.1%	$154.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$100.0M	$0	$0	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	$33.8M+44.4%	$23.4M+219.3%	-$19.6M-137.0%	$53.0M+172.3%	$19.5M+81.7%	$10.7M+164.2%	-$16.7M-221.2%	$13.8M
Capital Expenditures	$1.2M-14.8%	$1.5M-63.0%	$3.9M+12.9%	$3.5M+158.4%	$1.3M+72.8%	$779K+4.0%	$749K-56.5%	$1.7M
Free Cash Flow	$32.6M+48.3%	$22.0M+193.3%	-$23.6M-147.6%	$49.5M+173.3%	$18.1M+82.4%	$9.9M+157.0%	-$17.4M-244.7%	$12.0M
Investing Cash Flow	$27.3M-71.2%	$94.8M+1271.8%	$6.9M-70.4%	$23.4M+251.1%	-$15.5M+46.2%	-$28.8M-1116.1%	$2.8M+114.0%	-$20.2M
Financing Cash Flow	-$61K+99.9%	-$71.9M-125.6%	-$31.9M+67.8%	-$98.9M-4093.3%	$2.5M+275.0%	-$1.4M+66.3%	-$4.2M-336.7%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$572K-99.2%	$71.2M+141.5%	$29.5M-70.5%	$100.0M	$0	$0	$0	N/A

DVAX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	82.2%+3.8pp	78.4%+14.7pp	63.7%+3.2pp	60.5%-15.0pp	75.5%+4.4pp	71.1%
Operating Margin	-1.5%+14.4pp	-15.9%-55.2pp	39.2%+8.6pp	30.6%+177.5pp	-146.9%+236.0pp	-382.9%
Net Margin	9.8%+12.6pp	-2.8%-43.3pp	40.6%+23.1pp	17.5%+179.1pp	-161.6%+271.7pp	-433.3%
Return on Equity	4.6%+5.6pp	-1.0%-51.5pp	50.5%+16.0pp	34.5%+162.7pp	-128.2%+1712.6pp	-1840.8%
Return on Assets	2.8%+3.4pp	-0.6%-30.4pp	29.7%+22.4pp	7.4%+28.7pp	-21.3%+33.4pp	-54.7%
Current Ratio	10.80-3.0	13.81+7.7	6.11+4.4	1.75-2.0	3.75-0.2	3.93
Debt-to-Equity	0.65+0.0	0.60-0.1	0.70+0.7	0.00-3.1	3.06-18.5	21.54
FCF Margin	21.7%-19.8pp	41.5%+33.8pp	7.7%-66.5pp	74.2%+281.1pp	-206.9%+201.0pp	-407.9%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	84.8%-0.5pp	85.3%+5.5pp	79.8%-1.6pp	81.4%-2.4pp	83.8%0.0pp	83.8%+5.3pp	78.4%-6.0pp	84.4%
Operating Margin	22.4%+7.3pp	15.1%+49.8pp	-34.7%-32.4pp	-2.3%-14.8pp	12.5%+5.5pp	7.0%+42.0pp	-35.0%-19.7pp	-15.3%
Net Margin	28.4%+8.8pp	19.6%+160.6pp	-141.0%-150.8pp	9.8%-12.0pp	21.8%+6.4pp	15.4%+32.6pp	-17.2%-17.6pp	0.4%
Return on Equity	5.0%+1.2pp	3.8%+21.9pp	-18.1%-19.3pp	1.2%-1.4pp	2.6%+0.8pp	1.8%+3.2pp	-1.4%-1.4pp	0.0%
Return on Assets	2.8%+0.8pp	2.0%+12.2pp	-10.2%-10.9pp	0.7%-0.9pp	1.7%+0.5pp	1.1%+2.0pp	-0.9%-0.9pp	0.0%
Current Ratio	7.62+1.0	6.65-5.3	11.93+1.1	10.80-2.4	13.23-1.0	14.18-1.0	15.20+1.4	13.81
Debt-to-Equity	0.77-0.1	0.86+0.1	0.78+0.1	0.65+0.1	0.56-0.0	0.58-0.0	0.600.0	0.60
FCF Margin	34.4%+11.3pp	23.0%+57.6pp	-34.6%-103.3pp	68.8%+46.3pp	22.5%+9.0pp	13.5%+47.8pp	-34.3%-56.0pp	21.7%

Similar Companies

Evotec Ag EVO

$1.0B

Pacira Biosciences Inc PCRX

$878.2M

TILRAY BRANDS INC TLRY

$611.2M

Amphastar Pharma AMPH

$799.0M

Collegium Pharmaceutical Inc COLL

$1.0B

Frequently Asked Questions

What is Dynavax Technolo's annual revenue?

Dynavax Technolo (DVAX) reported $277.2M in total revenue for fiscal year 2024. This represents a 19.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Dynavax Technolo's revenue growing?

Dynavax Technolo (DVAX) revenue grew by 19.4% year-over-year, from $232.3M to $277.2M in fiscal year 2024.

Is Dynavax Technolo profitable?

Yes, Dynavax Technolo (DVAX) reported a net income of $27.3M in fiscal year 2024, with a net profit margin of 9.8%.

What is Dynavax Technolo's EBITDA?

Dynavax Technolo (DVAX) had EBITDA of $505K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Dynavax Technolo's gross margin?

Dynavax Technolo (DVAX) had a gross margin of 82.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Dynavax Technolo's operating margin?

Dynavax Technolo (DVAX) had an operating margin of -1.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Dynavax Technolo's net profit margin?

Dynavax Technolo (DVAX) had a net profit margin of 9.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Dynavax Technolo's return on equity (ROE)?

Dynavax Technolo (DVAX) has a return on equity of 4.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Dynavax Technolo's free cash flow?

Dynavax Technolo (DVAX) generated $60.2M in free cash flow during fiscal year 2024. This represents a -37.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Dynavax Technolo's operating cash flow?

Dynavax Technolo (DVAX) generated $66.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Dynavax Technolo's total assets?

Dynavax Technolo (DVAX) had $986.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Dynavax Technolo's capital expenditures?

Dynavax Technolo (DVAX) invested $6.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Dynavax Technolo spend on research and development?

Dynavax Technolo (DVAX) invested $61.5M in research and development during fiscal year 2024.

Does Dynavax Technolo buy back shares?

Yes, Dynavax Technolo (DVAX) spent $100.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Dynavax Technolo have outstanding?

Dynavax Technolo (DVAX) had 125M shares outstanding as of fiscal year 2024.

What is Dynavax Technolo's current ratio?

Dynavax Technolo (DVAX) had a current ratio of 10.80 as of fiscal year 2024, which is generally considered healthy.

What is Dynavax Technolo's debt-to-equity ratio?

Dynavax Technolo (DVAX) had a debt-to-equity ratio of 0.65 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dynavax Technolo's return on assets (ROA)?

Dynavax Technolo (DVAX) had a return on assets of 2.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Dynavax Technolo's Piotroski F-Score?

Dynavax Technolo (DVAX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dynavax Technolo's earnings high quality?

Dynavax Technolo (DVAX) has an earnings quality ratio of 2.44x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Dynavax Technolo cover its interest payments?

Dynavax Technolo (DVAX) has an interest coverage ratio of -0.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Dynavax Technolo?

Dynavax Technolo (DVAX) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.